Swedish Orphan Biovitrum AB (SOBI.ST) Stock Analysis & Winston Score

Swedish Orphan Biovitrum, known as Sobi, is a Swedish pharmaceutical company that makes medicines for rare diseases — conditions that affect very few people worldwide. Its main products treat hemophilia (a blood-clotting disorder), inflammatory diseases, and other uncommon genetic conditions. Sobi sells primarily to hospitals and specialist doctors across Europe and North America. Sobi earns money by selling its specialty drugs, often at high prices because rare-disease medicines face little competition and serve small patient populations. The company operates mainly in Europe but has expanded into the United States and other international markets, generating roughly $2 billion in annual revenue. Its moat comes from owning or licensing treatments for diseases where few alternatives exist, making it hard for competitors to displace it once a drug is established. The key risk is that its revenue is concentrated in a small number of products, so patent expirations or pipeline failures could meaningfully hurt the business.